Samsung Bioepis And Organon Line Up Interchangeable Adalimumab
Firms Prepare To File For Interchangeability With FDA For Hadlima Rival To Humira
Samsung Bioepis and Organon have announced results from an interchangeability study for their Hadlima biosimilar rival to Humira, also disclosing plans to file for a US interchangeability designation.
